Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2025

Genmab — Januar 2025

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    gentogen
    wrote on sidst redigeret af
    #27

    Med mindre JNJ træffer en lynhurtig beslutning, kommer Jan vel ikke til at sige noget som helst den 14. (andet end måske... lige at oplyse, om data er leveret som planlagt...). Men ja. Interessant om han overhovedet vil blive spurgt om det...

    1 Reply Last reply
    0
    • Legolas23L Offline
      Legolas23L Offline
      Legolas23
      wrote on sidst redigeret af
      #28

      Folk har solgt op til årsskiftet og genkøber vel igen. Jeg vil se en fortsat stigning før jeg tænker optrend

      1 Reply Last reply
      0
      • Y Offline
        Y Offline
        YPE
        wrote on sidst redigeret af
        #29

        Jeg ser helt klart positive signaler i måden aktien handles på i disse dage. Jeg venter gode nyheder.

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #30

          Gode nyheder plejer at have den modsatte virkning...

          1 Reply Last reply
          0
          • P Offline
            P Offline
            ProinvestorNEWS
            wrote on sidst redigeret af
            #31

            Danske helårsregnskaber 2024: Fokus på guidance, moderat vækst og fremtidens USA https://proinvestor.com/boards/123960

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #32

              At the recent IRT conference, Genmab USA’s IRT manager, Madeline Tremont, discussed how the company implemented IRT systems for their first-in-human (FIH) clinical trials. https://informaconnect.com/streamlining-first-in-human-trials-with-irt-systems/ What is Interactive Response Technology (IRT)? https://www.suvoda.com/insights/blog/what-is-interactive-response-technology-irt

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #33

                Top 25 Biotech Companies Heading Into 2025 https://www.genengnews.com/industry-news/top-25-biotech-companies-heading-into-2025/ - -
                will Genmab manage to get back into that list again...?

                1 Reply Last reply
                0
                • R Offline
                  R Offline
                  Raun
                  wrote on sidst redigeret af
                  #34

                  Efter at aktien er stille og roligt blevet nedbrudt henover mange måneder. Så er den i min verden bare blevet frigjort og det vi ser nu, - er at aktien bliver handlet frit og uden de såkaldte spekulanter.

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #35

                    Tyder på at prisen er over 3000 kr 😉

                    1 Reply Last reply
                    0
                    • R Offline
                      R Offline
                      Raun
                      wrote on sidst redigeret af
                      #36

                      😉

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #37

                        Life Science vinderaktier 2024 – sådan gik det https://proinvestor.com/investornyt/1262130/life-science-vinderaktier-2024-sadan-gik-det

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #38

                          Rybrevant https://finance.yahoo.com/news/rybrevant-amivantamab-vmjw-plus-lazcluze-130000654.html

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #39

                            J&J's Rybrevant, Lazcluze combo significantly improves survival over Tagrisso in lung cancer https://firstwordpharma.com/story/5925447

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #40

                              quite a few cancer centers in Asia added to the Acasunlimab /Pembro Ph3 trial. maybe the local presence/office in Japan helps here. a bit surprised they still name Biontech as Collaborator. https://clinicaltrials.gov/study/NCT06635824?tab=history&a=4&b=5#version-content-panel

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #41

                                Sachin Jain

                                Bank of America Securities Buy Kr.2,700.00 Reiterated Today

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #42

                                  Healthcare +0,6% (incl NBI +0,9%
                                  ) klarede sig rimeligt i et ellers ræverødt us her i aften.

                                  1 Reply Last reply
                                  0
                                  • A Offline
                                    A Offline
                                    Aaanditsgone
                                    wrote on sidst redigeret af
                                    #43

                                    Hvordan vurderer I gårsdagens Rybrevant-data? Er de ikke ret positive? Og gør det ikke GEN1286 ekstra spændende, når den ifølge Jan er meget bedre end amivantamab i prækliniske studier?

                                    1 Reply Last reply
                                    0
                                    • Y Offline
                                      Y Offline
                                      YPE
                                      wrote on sidst redigeret af
                                      #44

                                      Deadline for jnj beslutning må være 28. feb. - tror på en hurtig afklaring her i jan.

                                      1 Reply Last reply
                                      0
                                      • R Offline
                                        R Offline
                                        Raun
                                        wrote on sidst redigeret af
                                        #45

                                        Hvis der kommer en hurtig afklaring fra JnJ. Så er det fordi de kommer med et bud på Genmab.... - Ellers er jeg ret sikker på at afklaringen bliver trukket i det længste...

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #46

                                          Sachin Jain’s rating is based on Genmab’s promising pipeline and strategic developments. One of the key factors is the anticipated progress of the HexaBody-CD38, which is set for a critical opt-in decision by JNJ in the first quarter of 2025. This decision will determine the future of the drug, which has shown encouraging data in comparison to Darzalex in multiple myeloma.
                                          Another significant reason for the Buy rating is the potential of Rina-S,

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper